The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers

Elisa Gremese, Lianne Kearsley-Fleet, Jakub Závada, Merete Lund Hetland, Dan C. Nordström, Kalle J. Aaltonen, Joachim Listing, Angela Zink, Tamas Gati, Bernadette Rojkovich, Florenzo Iannone, Piet L.C.M. Van Riel, Martinus A.F.J. Van De Laar, Elisabeth Lie, Tore K. Kvien, Helena Canhão, João E. Fonseca, Žiga Rotar, Estibaliz Loza, Loreto CarmonaJohan Askling, Kari Johansson, Axel Finckh, William G. Dixon, Kimme L. Hyrich

Risultato della ricerca: Contributo in rivistaArticolo in rivista

18 Citazioni (Scopus)

Abstract

Under the auspices of the European League Against Rheumatism (EULAR), a study group of investigators representing European biologic DMARD (bDMARD) registers was convened. The purpose of this initial assessment was to collect and compare a cross section of patient characteristics and collate information on the availability of potential confounders within these registers.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaTHE JOURNAL OF RHEUMATOLOGY
DOI
Stato di pubblicazionePubblicato - 2014

Keywords

  • biologic therapies
  • epidemiology
  • outcome measures
  • rheumatoid arthritis
  • study design

Fingerprint Entra nei temi di ricerca di 'The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers'. Insieme formano una fingerprint unica.

Cita questo